-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The following content is only for reference by medical pharmacy professionals.
If you are not the aforementioned professionals, please leave this page and finally wait for you! In June 2021, the new version of the "American College of Rheumatology (ACR) Rheumatoid Arthritis (RA) Treatment Guidelines" was officially released [1]
.
After six years, ACR updated the RA guidelines again
.
On the basis of the 2015 version of the guidelines [2], combined with the new evidence and new developments in the field of RA in recent years, it provides detailed treatment opinions for rheumatologists
.
In terms of specific treatment recommendations, the update of the new version of the guidelines mainly includes the following points: The 1.
2015 version of the guidelines points out that for RA patients with low/medium/high disease activity, it is recommended to use traditional synthetic disease-improving anti-rheumatic drugs (csDMARD) monotherapy.
The new version of the guidelines recommends that patients with RA with low disease activity may try to use hydroxychloroquine or sulfasalazine in the initial treatment
.
2.
The 2015 version of the guidelines recommends that RA patients who have achieved clinical remission can reduce DMARDs, while the new version of the guidelines points out that for patients who have achieved remission or low disease activity (LDA), there is still a lack of research data on when to reduce the drug and how to achieve the best drug reduction For reference, the expert group recommends that when patients are willing to reduce the dose of DMARD, they can consider reducing the drug carefully
.
During the drug reduction period, the patient should be carefully evaluated, and if there is a recurrence, the previous plan should be resumed immediately
.
3.
The new version of the guide updated several recommendations against the use of glucocorticoid therapy, and pointed out that there are often certain difficulties in reducing the dose of glucocorticoid, which will cause unnecessary long-term use
.
In recent years, more and more evidence has shown that glucocorticoids have a negative impact on the long-term prognosis of patients with RA or other rheumatic diseases, including the risks of infection, osteoporosis, and cardiovascular disease.
.
If you are not the aforementioned professionals, please leave this page and finally wait for you! In June 2021, the new version of the "American College of Rheumatology (ACR) Rheumatoid Arthritis (RA) Treatment Guidelines" was officially released [1]
.
After six years, ACR updated the RA guidelines again
.
On the basis of the 2015 version of the guidelines [2], combined with the new evidence and new developments in the field of RA in recent years, it provides detailed treatment opinions for rheumatologists
.
In terms of specific treatment recommendations, the update of the new version of the guidelines mainly includes the following points: The 1.
2015 version of the guidelines points out that for RA patients with low/medium/high disease activity, it is recommended to use traditional synthetic disease-improving anti-rheumatic drugs (csDMARD) monotherapy.
The new version of the guidelines recommends that patients with RA with low disease activity may try to use hydroxychloroquine or sulfasalazine in the initial treatment
.
2.
The 2015 version of the guidelines recommends that RA patients who have achieved clinical remission can reduce DMARDs, while the new version of the guidelines points out that for patients who have achieved remission or low disease activity (LDA), there is still a lack of research data on when to reduce the drug and how to achieve the best drug reduction For reference, the expert group recommends that when patients are willing to reduce the dose of DMARD, they can consider reducing the drug carefully
.
During the drug reduction period, the patient should be carefully evaluated, and if there is a recurrence, the previous plan should be resumed immediately
.
3.
The new version of the guide updated several recommendations against the use of glucocorticoid therapy, and pointed out that there are often certain difficulties in reducing the dose of glucocorticoid, which will cause unnecessary long-term use
.
In recent years, more and more evidence has shown that glucocorticoids have a negative impact on the long-term prognosis of patients with RA or other rheumatic diseases, including the risks of infection, osteoporosis, and cardiovascular disease.
.
